The National Institute for Health and Clinical Excellence (NICE) Maintains Previous Recommendation for EXOGEN Ultrasound Bone Healing System
Bioventus has received notice from the United Kingdom's National Institute for Health and Clinical Excellence (NICE) regarding the indication of EXOGEN for the treatment of nonunions of long bones.
EXOGEN uses Low Intensity Pulsed Ultrasound (LIPUS) to stimulate the physiological process of bone healing and enhance fracture healing. It has a healing rate of 86% in nonunions and accelerates the healing of fresh fractures by 38%.
After reviewing a large body of clinical evidence, NICE maintains the recommendation to use EXOGEN for the treatment of nonunions of long bones. NICE defines nonunion as a fracture that does not heal after nine months.
Furthermore, by increasing the cost of surgery by 25% since 2013, EXOGEN treatment has been shown to offer twice the savings by avoiding a surgical procedure than previously published, from £1,164 to £2,407 per patient.
The indication of EXOGEN is supported by multiple level 1 studies in which the positive effects offered by LIPUS technology are demonstrated.
